OncoMatch

OncoMatch/Clinical Trials/NCT06404697

Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients

Is NCT06404697 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for breast cancer.

Phase 2RecruitingRuijin HospitalNCT06404697Data as of May 2026

cN3c breast cancer with ipsilateral supraclavicular (SCV) lymph nodal (SCLN) metastasis is known to have a dismal prognosis. Currently, the combined-modality therapy consisting of primary systemic therapy (PST), subsequent local and/or systemic therapy based on response is the standard of care. However, the value of giving radiotherapy (RT) boost to SCV region remains uncertain in cN3c patients. This study aimed to assess the efficacy and safety of RT boost to the SCV area in high-risk cN3c breast cancer patients based on nodal response following PST.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: ESR1 expression (testing required; no eligibility threshold specified)

Availability of hormonal receptor (ER/PR)...status for the primary breast lesion

Required: PR (PGR) expression (testing required; no eligibility threshold specified)

Availability of hormonal receptor (ER/PR)...status for the primary breast lesion

Required: HER2 (ERBB2) expression (testing required; no eligibility threshold specified)

Availability of...HER2...status for the primary breast lesion

Required: MKI67 expression (testing required; no eligibility threshold specified)

Availability of...Ki-67 status for the primary breast lesion

Disease stage

Required: Stage CN3C

Clinical diagnosis of cN3c; Patients with T4 staging of the primary tumor [excluded]

Prior therapy

Must have received: neoadjuvant therapy — neoadjuvant

Receipt of neoadjuvant therapy, guided by the attending physician and current treatment guidelines

Must have received: curative-intent breast cancer surgery — post-neoadjuvant

Undergoing curative-intent breast cancer surgery post-neoadjuvant therapy

Cannot have received: radiation therapy to the neck, chest, or ipsilateral axilla

History of prior radiation therapy to the neck, chest, or ipsilateral axilla

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify